# Lombard Medical Technologies

Lombard Medical Technologies is an Asset Manager based in Didcot, United Kingdom.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Didcot, United Kingdom
- **Region:** Europe
- **Address:** Didcot, United Kingdom
- **Assets under management:** Undisclosed

## Regulatory record

- **Reports private funds:** No

## About

Lombard Medical Technologies was a UK-based medical device company that designed and commercialized stent-grafts for aortic aneurysm repair. Its primary product was the Aorfix endovascular stent-graft system, which received CE Mark approval in 2004 and FDA approval in 2013. The company targeted physicians treating abdominal aortic aneurysms, aiming to offer a system compatible with challenging anatomy. The company raised over $60M in venture funding from investors including Arpida, MVM Life Science Partners, and Foresight Group. Its strategy centered on direct sales in Europe and a US commercial launch following FDA clearance. Lombard also filed multiple patents related to stent-graft design, including a bifurcated system. By early 2017, the company had incurred significant operating losses and reported annual revenue of approximately $5M. In June 2017, Shanghai-based MicroPort Scientific announced the acquisition of Lombard Medical for an undisclosed sum, valuing the company at a fraction of its cumulative venture investment. The acquisition gave MicroPort access to the Aorfix platform and a US regulatory clearance. Lombard Medical's structural differentiator was its focus on a single product line within a niche of vascular surgery, competing against established giants like Medtronic and Cook Medical. This narrow focus, combined with limited commercialization resources, contributed to its eventual acquisition.

## Sectors

- Medical Devices
- MedTech

## Questions

### Who were the primary investors in Lombard Medical Technologies?

Lombard raised venture capital from Arpida, MVM Life Science Partners, and Foresight Group, among others (per SEC filings and press releases, 2004-2010). The company completed multiple rounds totaling over $60M before its acquisition.

### What was the Aorfix stent-graft system?

The Aorfix was an endovascular stent-graft designed to treat abdominal aortic aneurysms, with a specific advantage in angulated neck anatomy. It received CE Mark approval in 2004 and FDA approval in 2013 (per the FDA, 2013).

### Why did MicroPort Scientific acquire Lombard Medical?

MicroPort, a Shanghai-based medical device group, acquired Lombard in June 2017 for an undisclosed sum to gain access to the Aorfix platform and its US regulatory clearance (per MicroPort press release, June 2017). The deal expanded MicroPort's vascular portfolio.

### Did Lombard Medical generate significant revenue?

Lombard reported annual revenue of approximately $5M in fiscal 2016, well short of covering its operating expenses (per the company's annual report, 2016). The company had accumulated substantial losses prior to the acquisition.

### Which markets did Lombard target?

Lombard sold its products in Europe (including the UK and Germany) and pursued US commercialization after obtaining FDA approval in 2013 (per company filings, 2013). The US launch was limited and never reached scale.

## Related profiles

- [Christie Digital Systems](https://altss.com/profile/christie-digital-systems)
- [Monaker Group](https://altss.com/profile/monaker-group)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/lombard-medical-technologies

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology